Manila Times Business
SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting
Ross Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurgi Camblong nominated for election as Chairman of the Board BOSTON and ROLLE, Switzerland, June 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today confirmed, ahead of its 2026 Annual General Meeting (AGM) scheduled for June 18, 2026, the leadership changes first announced in January 2026. The Board has appointed Ross Muken, currently Pres
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Cellebrite Launches the New Age of Investigations with Genesis, Now Generally Available
Just now
Adaptive ML and AT&T Expand AI Collaboration to Scale Specialized Models Across Enterprise Workflows
Just now
LEIFRAS Co., Ltd. Announces Entry into Kawasaki City Through New School Club Support Contract
Just now
TOYO Co., Ltd. Secures Two Major Supply Agreements Totaling $185.6 Million in Cumulative Purchase Orders for the U.S. Market
Just now